Clinical Research Directory
Browse clinical research sites, groups, and studies.
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.
Official title: PARP-1 Targeting With the Novel Radiotracer [18F]FTT in Pancreatic Neuroendocrine Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2025-10-01
Completion Date
2027-09
Last Updated
2026-02-02
Healthy Volunteers
No
Interventions
[18F]FluorThanatrace
Intravenous injection of ≤ 12 mCi of \[18F\]FTT for whole-body PET CT dynamic imaging and subsequent static scan.
Locations (1)
University of Pennsylvania, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States